Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer

NCT03310008 is registered in ClinicalTrials.gov with Celyad Oncology SA as lead sponsor.

NCT NCT03310008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03310008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer
Lead sponsor
Celyad Oncology SA
Phase
Phase 1
Overall status
Unknown status
Start date
August 7, 2017
Completion date
May 31, 2021
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer liver metastasis